Diana Martínez Saucedo, PhD
About
Titles
Postdoctoral Associate
Biography
My goal is to develop novel therapies for pancreatic cancer by understanding how alternative splicing drives antitumor immunity and serves as a potential therapeutic target.
I earned my Ph.D. in Biomedical Sciences at the National Autonomous University of Mexico (UNAM). My research projects aimed to elucidate pathways and mechanisms associated with anti-inflammatory M2-macrophages to reduce the inflammatory process. During my Ph.D., I discovered that microRNAs are crucial to reducing the expression of inflammatory mediators in macrophages and inducing the expression of M2-associated molecules. This finding suggests reprogramming macrophages through the identified pathways can guide the development of new therapies across inflammatory pathologies in MS and diabetes type 1, among others.
This understanding of post-transcriptional events' impact on cells motivated me to study the role of alternative splicing in one of the most aggressive and therapeutically resistant cancers: Pancreatic cancer. Understanding the microenvironment of the tumors, tumor cell interaction with the immune system, and the role of splicing in these contexts is crucial to developing better therapeutic approaches.
Postdoctoral Fellowship: Leslie Warner, Yale Cancer Center.
Education & Training
- PhD
- Universidad Nacional Autonoma de Mexico, Biomedical Sciences (2019)
- Research Associate
- Nationwide Children's Hospital (2017)
- BS
- Universidad Nacional Autonoma de Mexico, Biologia (2011)
Research
Publications
2019
Helminth-derived molecules inhibit colitis-associated colon cancer development through NF-κB and STAT3 regulation.
Callejas BE, Mendoza-Rodríguez MG, Villamar-Cruz O, Reyes-Martínez S, Sánchez-Barrera CA, Rodríguez-Sosa M, Delgado-Buenrostro NL, Martínez-Saucedo D, Chirino YI, León-Cabrera SA, Pérez-Plasencia C, Vaca-Paniagua F, Arias-Romero LE, Terrazas LI. Helminth-derived molecules inhibit colitis-associated colon cancer development through NF-κB and STAT3 regulation. Int J Cancer 2019, 145: 3126-3139. PMID: 31407335, DOI: 10.1002/ijc.32626.Peer-Reviewed Original ResearchTaenia crassiceps-Excreted/Secreted Products Induce a Defined MicroRNA Profile that Modulates Inflammatory Properties of Macrophages.
Martínez-Saucedo D, Ruíz-Rosado JD, Terrazas C, Callejas BE, Satoskar AR, Partida-Sánchez S, Terrazas LI. Taenia crassiceps-Excreted/Secreted Products Induce a Defined MicroRNA Profile that Modulates Inflammatory Properties of Macrophages. J Immunol Res 2019, 2019: 2946713. PMID: 31218234, DOI: 10.1155/2019/2946713.Peer-Reviewed Original Research
2018
Parasites as negative regulators of cancer.
Callejas BE, Martínez-Saucedo D, Terrazas LI. Parasites as negative regulators of cancer. Biosci Rep 2018, 38 PMID: 30266743, DOI: 10.1042/BSR20180935.Peer-Reviewed Original ResearchAngiotensin II receptor I blockade prevents stenosis of tissue engineered vascular grafts
de Dios Ruiz‐Rosado J, Lee Y, Mahler N, Yi T, Robledo‐Avila F, Martinez‐Saucedo D, Lee AY, Shoji T, Heuer E, Yates AR, Pober JS, Shinoka T, Partida‐Sanchez S, Breuer CK. Angiotensin II receptor I blockade prevents stenosis of tissue engineered vascular grafts. The FASEB Journal 2018, 32: 6822-6832. PMID: 29906242, PMCID: PMC6219835, DOI: 10.1096/fj.201800458.Peer-Reviewed Original ResearchAngiotensin II receptor ITEVG stenosisPrevents stenosisMononuclear cellsAngiotensin II type 1 receptor antagonistReceptor IBone marrow-derived mononuclear cellsShort-term losartan treatmentType 1 receptor antagonistMarrow-derived mononuclear cellsVascular graftsShort-term administrationCongenital heart surgeryTissue-engineered vascular graftsLong-term patencyWidespread clinical useLosartan treatmentPharmacologic treatmentAcute phaseMonocyte infiltrationHeart surgeryReceptor antagonistCCR2 knockoutRecipient miceClinical trials
2017
Helminth-induced Ly6C(hi) monocyte-derived alternatively activated macrophages suppress experimental autoimmune encephalomyelitis.
Terrazas C, de Dios Ruiz-Rosado J, Amici SA, Jablonski KA, Martinez-Saucedo D, Webb LM, Cortado H, Robledo-Avila F, Oghumu S, Satoskar AR, Rodriguez-Sosa M, Terrazas LI, Guerau-de-Arellano M, Partida-Sánchez S. Helminth-induced Ly6C(hi) monocyte-derived alternatively activated macrophages suppress experimental autoimmune encephalomyelitis. Sci Rep 2017, 7: 40814. PMID: 28094319, DOI: 10.1038/srep40814.Peer-Reviewed Original Research In Press
2015
Uncovering Leishmania-macrophage interplay using imaging flow cytometry.
Terrazas C, Oghumu S, Varikuti S, Martinez-Saucedo D, Beverley SM, Satoskar AR. Uncovering Leishmania-macrophage interplay using imaging flow cytometry. J Immunol Methods 2015, 423: 93-8. PMID: 25967951, DOI: 10.1016/j.jim.2015.04.022.Peer-Reviewed Original ResearchThe macrophage galactose-type lectin-1 (MGL1) recognizes Taenia crassiceps antigens, triggers intracellular signaling, and is critical for resistance to this infection.
Montero-Barrera D, Valderrama-Carvajal H, Terrazas CA, Rojas-Hernández S, Ledesma-Soto Y, Vera-Arias L, Carrasco-Yépez M, Gómez-García L, Martínez-Saucedo D, Becerra-Díaz M, Terrazas LI. The macrophage galactose-type lectin-1 (MGL1) recognizes Taenia crassiceps antigens, triggers intracellular signaling, and is critical for resistance to this infection. Biomed Res Int 2015, 2015: 615865. PMID: 25664320, DOI: 10.1155/2015/615865.Peer-Reviewed Original Research
Teaching & Mentoring
Mentoring
Deanne Yugawa
Graduate student2022 - 2025